The discovery of the host genome factors of IL-28B was a milestone since it demonstrated and explained the influence of genetic variations and ethnicity on the efficacy of interferon-based therapy for patients with GT1 CHC [28], [29]. This evidence concerns the gene IFNL3 and cryohydrocytosis.